Time trends in antithrombotic therapy prescription patterns: Real-world monocentric study in hospitalized patients with atrial fibrillation

Figure 1 Time trends in the number of hospital discharges (total, with and without atrial fibrillation diagnosis); discharges with atrial fibrillation were further divided into the main or secondary diagnosis. AF: Atrial fibrillation.

Figure 2  Study flowchart.

Figure 3 Prevalence of different antithrombotic treatments as a percentage of total antithrombotic treatments. ASA: Acetylsalicylic acid; LMWH: Low molecular weight heparin.

Figure 4 Time trends over three-year periods (from 2010-2012 to 2019-2021) of the prevalence of different antithrombotic treatments as a percentage of total antithrombotic treatments. LMWH: Low molecular weight heparin.

Figure 5 Time trends by year (from 2010 to 2021) in prescription of different antithrombotic treatments (absolute number). APT: Antiplatelet treatment; VKA: vitamin K antagonist; DOAC: Direct oral anticoagulant; OAT: Oral antithrombotic therapy; TAT: Triple antithrombotic therapy; DAT: Double antithrombotic therapy.

Figure 6 Time trends by year (from 2010 to 2021) in prescription of different antithrombotic treatments (as a percentage of total patients). APT: Antiplatelet treatment; VKA: vitamin K antagonist; DOAC: Direct oral anticoagulant; OAT: Oral antithrombotic therapy; TAT: Triple antithrombotic therapy; DAT: Double antithrombotic therapy.